Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) (CONCERTO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01707992
Recruitment Status : Completed
First Posted : October 16, 2012
Results First Posted : March 13, 2019
Last Update Posted : March 13, 2019
Sponsor:
Information provided by (Responsible Party):
Teva Pharmaceutical Industries ( Teva Branded Pharmaceutical Products, R&D Inc. )

Brief Summary:
This is a multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study followed by active treatment, to evaluate the efficacy, safety and tolerability of two doses of oral administration of laquinimod in participants with RRMS. The study has 2 periods: Period 1, the double-blind, placebo-controlled period (up to 24 months) and Period 2, the active treatment period (24 months).

Condition or disease Intervention/treatment Phase
Multiple Sclerosis Drug: Laquinimod Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 2199 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Actual Study Start Date : February 20, 2013
Actual Primary Completion Date : April 13, 2015
Actual Study Completion Date : July 4, 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Placebo Comparator: Placebo-Controlled Phase: Placebo
Participants will receive 2 capsules of placebo (matching to laquinimod 0.6 milligrams [mg]) once daily orally for up to 24 months.
Drug: Placebo
Placebo matching to laquinimod will be administered as per the schedule specified in the respective arms.

Experimental: Placebo-Controlled Phase: Laquinimod 0.6 mg
Participants will receive 1 capsule of laquinimod 0.6 mg and 1 capsule of matching placebo once daily orally for up to 24 months.
Drug: Laquinimod
Laquinimod will be administered as per the dose and schedule specified in the respective arms.

Drug: Placebo
Placebo matching to laquinimod will be administered as per the schedule specified in the respective arms.

Experimental: Placebo-Controlled Phase: Laquinimod 1.2 mg
Participants will receive laquinimod 1.2 mg (2 capsules of laquinimod 0.6 mg each) once daily orally for up to 24 months.
Drug: Laquinimod
Laquinimod will be administered as per the dose and schedule specified in the respective arms.

Experimental: Active Treatment Phase: Laquinimod 0.6 mg
Participants who completed the placebo-controlled phase on placebo and on laquinimod 0.6 mg treatment group after 01 January 2016, will receive 1 capsule of laquinimod 0.6 mg and 1 capsule of matching placebo once daily orally for 24 months.
Drug: Laquinimod
Laquinimod will be administered as per the dose and schedule specified in the respective arms.

Drug: Placebo
Placebo matching to laquinimod will be administered as per the schedule specified in the respective arms.

Experimental: Active Treatment Phase: Laquinimod 1.2 mg
Participants who completed the placebo-controlled phase on placebo and on laquinimod 1.2 mg treatment group prior to 01 January 2016, will receive laquinimod 1.2 mg (2 capsules of laquinimod 0.6 mg each) once daily orally for 24 months.
Drug: Laquinimod
Laquinimod will be administered as per the dose and schedule specified in the respective arms.

No Intervention: Active Treatment Phase: Off Drug
Participants who were discontinued from treatment with laquinimod 1.2 mg during the placebo-controlled phase due to sponsor decision after 01 January 2016 will continue the active-treatment phase off drug for 24 months.



Primary Outcome Measures :
  1. Placebo-Controlled Phase: Time to Confirmed Disease Progression (CDP) Confirmed After At Least 3 Months (Number of Participants With CDP After At Least 3 Months) [ Time Frame: Baseline to Month 24 ]
    Time to CDP was defined as the time to a sustained increase in Kurtzke's Expanded Disability Status Scale (EDSS) score of at least 1 point if baseline EDSS score was less than or equal to 5.0, or at least 0.5 point if the baseline EDSS score was 5.5, over a period of at least three months. EDSS assesses disability in 8 functional systems with an overall score ranging from 0 (normal) to 10 (death due to multiple sclerosis [MS]). Data is presented as distribution of CDP (number of participants with CDP) sustained for 3 months.


Secondary Outcome Measures :
  1. Placebo-Controlled Phase: Percent Change From Baseline in Brain Volume at Month 15 [ Time Frame: Baseline, Month 15 ]
    Brain atrophy was defined by the percent change in brain volume from baseline to Month 15. For participants who prematurely discontinued treatment or completed the placebo-controlled phase before Month 15, the last available measurement was used, provided it was performed at least 9 months following the initiation of study drug.

  2. Placebo-Controlled Phase: Time to First Confirmed Relapse (Number of Participants With Confirmed Relapse) [ Time Frame: Baseline to Month 24 ]
    Relapse was defined as appearance of one or more new neurological abnormalities or reappearance or worsening of one or more previously observed neurological abnormalities, lasting for at least 48 hours (in absence of fever or any infection) and immediately preceded by an improving neurological state of at least 30 days from onset of previous relapse. An event was counted as a relapse only when the participant's symptoms were accompanied by observed objective neurological changes, consistent with an increase of at least 0.5 in EDSS; or one grade in score of 2 or more of 7 Functional Systems (FS) (excluding changes in bowel or bladder function or cognition); or 2 grades in score of one of the FS as compared to previous evaluation. EDSS assesses disability in 8 FS with an overall score ranging from 0 (normal) to 10 (death due to MS). Data is presented as distribution of relapsing participants (number of participants with confirmed relapse).

  3. Placebo-Controlled Phase: Time to CDP Confirmed After At Least 6 Months (Number of Participants With CDP After At Least 6 Months) [ Time Frame: Baseline to Month 24 ]
    Time to CDP was defined as the time to a sustained increase in Kurtzke's EDSS score of at least 1 point if baseline EDSS score was less than or equal to 5.0, or at least 0.5 point if the baseline EDSS score was 5.5, over a period of at least 6 months. EDSS assesses disability in 8 functional systems with an overall score ranging from 0 (normal) to 10 (death due to MS). Data is presented as distribution of CDP (number of participants with CDP) sustained for 6 months.

  4. Placebo-Controlled Phase: Time to CDP Confirmed After At Least 9 Months (Number of Participants With Confirmed Relapse After At Least 9 Months) [ Time Frame: Baseline to Month 24 ]
    Time to CDP was defined as the time to a sustained increase in Kurtzke's EDSS score of at least 1 point if baseline EDSS score was less than or equal to 5.0, or at least 0.5 point if the baseline EDSS score was 5.5, over a period of at least 9 months. EDSS assesses disability in 8 functional systems with an overall score ranging from 0 (normal) to 10 (death due to MS). Data is presented as distribution of CDP (number of participants with CDP) sustained for 9 months.


Other Outcome Measures:
  1. Placebo-Controlled Phase: Number of Participants With Adverse Events (AEs) [ Time Frame: Baseline up to Month 24 ]
    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious AEs.

  2. Active-Treatment Phase: Number of Participants With AEs [ Time Frame: Baseline (Month 0 of active-treatment phase/Month 24 of placebo-controlled phase) up to Month 24 of active-treatment phase ]
    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious AEs.

  3. Placebo-Controlled Phase: Number of Participants With Clinically Significant Vital Signs Abnormalities [ Time Frame: Baseline up to Week 24 ]
    Clinically significant vital signs abnormalities included: Pulse rate: greater than or equal to (>=) 120 beats per minute (bpm) and increase from baseline of >=30 bpm, <=45 bpm and decrease from baseline of >=30 bpm; Systolic blood pressure: >=180 millimeters of mercury (mmHg) and increase from baseline of >=30 mmHg, <=90 and decrease from baseline of >=30 mmHg; Diastolic blood pressure: >=100 mmHg and increase from baseline of >=20 mmHg, <=50 mmHg and decrease from baseline of >=20 mmHg.

  4. Active-Treatment Phase: Number of Participants With Clinically Significant Vital Signs Abnormalities [ Time Frame: Baseline (Month 0 of active-treatment phase/Month 24 of placebo-controlled phase) up to Month 24 of active-treatment phase ]
    Clinically significant vital signs abnormalities included: Pulse rate: >=120 bpm and increase from baseline of >=30 bpm, <=45 bpm and decrease from baseline of >=30 bpm; Systolic blood pressure: >=180 mmHg and increase from baseline of >=30 mmHg, <=90 and decrease from baseline of >=30 mmHg; Diastolic blood pressure: >=100 mmHg and increase from baseline of >=20 mmHg, <=50 mmHg and decrease from baseline of >=20 mmHg.

  5. Placebo-Controlled Phase: Number of Participants With Shift From Baseline to Endpoint in Electrocardiogram (ECG) Parameters [ Time Frame: Baseline, Endpoint (Month 24) ]
    ECG parameters included: PR interval, QRS interval, QT interval corrected using the Fridericia formula (QTcF) and QT interval corrected using the Bazett's formula (QTcB). Shifts represented as Baseline - endpoint value (last observed post-baseline value). Abnormal NCS indicated an abnormal but not clinically significant finding. Abnormal CS indicated an abnormal and clinically significant finding.

  6. Active Treatment Phase: Number of Participants With Shift From Baseline to Endpoint in ECG Parameters [ Time Frame: Baseline (Month 0 of active-treatment phase/Month 24 of placebo-controlled phase), endpoint (Month 24 of active-treatment phase) ]
    ECG parameters included: PR interval, QRS interval, QTcF and QTcB. Shifts represented as Baseline - endpoint value (last observed post-baseline value). Abnormal NCS indicated an abnormal but not clinically significant finding. Abnormal CS indicated an abnormal and clinically significant finding.

  7. Placebo-Controlled Phase: Number of Participants With Potentially Clinically Significant Abnormal Serum Chemistry [ Time Frame: Baseline up to Month 24 ]
    Potentially clinically significant serum chemistry abnormalities included: Glucose <=3 and >=13.88 millimoles per liter (mmol/L); Alanine aminotransferase (ALT) (in units per liter [U/L]), aspartate aminotransferase (AST) (in U/L), alkaline phosphatase (in U/L), gamma-glutamyltransferase (GGT) (in U/L), creatine phosphokinase (CPK) (in U/L), C-reactive protein (CRP) (in milligrams per liter [mg/L]), pancreatic amylase (in U/L)>=3 * upper limit of normal (ULN); Fibrinogen >=6 grams per liter (gm/L); Sodium <=130 and >=150 mmol/L; Potassium <=3.2 and >=5.5 mmol/L; Calcium <=1.87 and >=2.75 mmol/L; Phosphate <=0.65 and >=1.61 mmol/L.

  8. Active Treatment Phase: Number of Participants With Potentially Clinically Significant Abnormal Serum Chemistry [ Time Frame: Baseline (Month 0 of active-treatment phase/Month 24 of placebo-controlled phase) up to Month 24 of active-treatment phase ]
    Potentially clinically significant serum chemistry abnormalities included: Glucose <=3 and >=13.88 mmol/L; ALT (in U/L), AST (in U/L), alkaline phosphatase (in U/L), GGT (in U/L), CPK (in U/L), CRP (in mg/L), pancreatic amylase (in U/L)>=3 * ULN; Fibrinogen >=6 gm/L; Sodium <=130 and >=150 mmol/L; Potassium <=3.2 and >=5.5 mmol/L; Calcium <=1.87 and >=2.75 mmol/L; Phosphate <=0.65 and >=1.61 mmol/L; Blood urea nitrogen (in mmol/L); Total bilirubin >=28 micromols per liter (micromols/L); Creatinine >=117 micromols/L; Albumin <=25 gm/L.

  9. Placebo-Controlled Phase: Number of Participants With Potentially Clinically Significant Abnormal Hematology Values [ Time Frame: Baseline up to Month 24 ]
    Potentially clinically significant hematological abnormalities included: Hemoglobin <=11.5 grams per deciliter (gm/dL) in males and <=10 gm/dL in females; White blood cells (WBCs) count <=2.5 and >=21*10^9 per liter (L); Absolute neutrophil count (ANC) <=1.49*10^9 per L; Platelet count <=100 and >=600*10^9 per L.

  10. Active Treatment Phase: Number of Participants With Potentially Clinically Significant Abnormal Hematology Values [ Time Frame: Baseline (Month 0 of active-treatment phase/Month 24 of placebo-controlled phase) up to Month 24 of active-treatment phase ]
    Potentially clinically significant hematological abnormalities included: Hemoglobin <=11.5, >=20 gm/dL in males, and <=10, >=18.5 gm/dL in females; WBCs count <=2.5 and >=21*10^9 per L; ANC <=1.49*10^9 per L; Platelet count <=100 and >=600*10^9 per L.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participants must have a confirmed and documented multiple sclerosis (MS) diagnosis as defined by the Revised McDonald criteria, with relapse onset disease or a relapsing-remitting disease course.
  • Participants must be ambulatory with Kurtzke's expanded disability status scale (EDSS) score of 0 to 5.5 in both screening and randomization visits.
  • Participants must be in a stable neurological condition, relapse-free and free of any corticosteroid treatment [intravenous (IV), intramuscular (IM) and/or per os (PO)/oral] or adrenocorticotrophic hormone, 60 days prior to randomization.
  • Participants must have experienced at least one documented relapse in the 12 months prior to randomization.
  • Participants must have disease duration of not more than 15 years.
  • Women of child-bearing potential (for example, women who are not postmenopausal or surgically sterilized) must practice an acceptable method of birth control for 30 days before taking the study drug and two acceptable methods of birth control during the duration of the study and until 30 days after the last dose of study medication.

    • Additional criteria apply, please contact the investigator for more information.

Exclusion Criteria:

  • Participants with progressive forms of MS.
  • Participants with neuromyelitis optica.
  • Use of experimental or investigational drugs and/or participation in drug clinical studies within the 6 months prior to randomization.
  • Use of immunosuppressive agents or cytotoxic agents, including cyclophosphamide, within 6 months prior to randomization.
  • Use of either of the following within 2 years prior to randomization visit: natalizumab (Tysabri®), rituximab, ocrelizumab, atacicept, belimumab, or ofatumumab.
  • Use of teriflunomide (Aubagio®) within 2 years prior to randomization, except if active washout (with either cholestyramine or activated charcoal) was done 2 months or more prior to randomization.
  • Previous treatment with glatiramer acetate (Copaxone®) Interferon β (either 1a or 1b), fingolimod (Gilenya®), dimethyl fumarate (Tecfidera®) or intravenous immunoglobulins within 2 months prior to randomization.
  • Chronic (more than 30 consecutive days) systemic (IV, IM or PO) corticosteroid treatment within 2 months prior to randomization.
  • Previous use of mitoxantrone (Novantrone®), cladribine, or alemtuzumab (Lemtrada®).
  • Previous use of laquinimod.
  • Previous total body irradiation or total lymphoid irradiation.
  • Previous stem cell treatment, autologous bone marrow transplantation or allogenic bone marrow transplantation.
  • Use of moderate/strong inhibitors of cytochrome P450 (CYP) 3A4 within 2 weeks prior to randomization.
  • Use of inducers of CYP3A4 within 2 weeks prior to randomization visit.
  • Pregnancy or breastfeeding.
  • A known history of sensitivity to gadolinium (Gd).
  • Inability to successfully undergo magnetic resonance imaging (MRI) scanning.
  • Participants who underwent endovascular treatment for chronic cerebrospinal venous insufficiency within 3 months prior to randomization.

    • Additional criteria apply, please contact the investigator for more information.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01707992


  Hide Study Locations
Locations
Layout table for location information
United States, Alabama
Teva Investigational Site 10329
Cullman, Alabama, United States, 35058
United States, Arizona
Teva Investigational Site 10349
Sun City, Arizona, United States, 85351
Teva Investigational Site 10342
Tucson, Arizona, United States, 85741-3537
United States, California
Teva Investigational Site 10310
Fresno, California, United States, 93710
United States, Colorado
Teva Investigational Site 10307
Aurora, Colorado, United States, 80045
Teva Investigational Site 10334
Centennial, Colorado, United States, 80112
Teva Investigational Site 10332
Fort Collins, Colorado, United States, 80528
United States, Florida
Teva Investigational Site 10316
Coral Gables, Florida, United States, 33146
Teva Investigational Site 10341
Saint Petersburg, Florida, United States, 33701
Teva Investigational Site 10308
Sarasota, Florida, United States, 34233
Teva Investigational Site 10315
Sunrise, Florida, United States, 33351
Teva Investigational Site 10323
Tampa, Florida, United States, 33606
United States, Illinois
Teva Investigational Site 10350
Chicago, Illinois, United States, 60612
Teva Investigational Site 10345
Evanston, Illinois, United States, 60201
Teva Investigational Site 10343
Northbrook, Illinois, United States, 60062
United States, Indiana
Teva Investigational Site 10339
Fort Wayne, Indiana, United States, 46805
United States, Kansas
Teva Investigational Site 10348
Lenexa, Kansas, United States, 66214
United States, Massachusetts
Teva Investigational Site 10338
Boston, Massachusetts, United States, 02215
United States, North Carolina
Teva Investigational Site 10346
Advance, North Carolina, United States, 27006
Teva Investigational Site 10347
Winston-Salem, North Carolina, United States, 27157
United States, Ohio
Teva Investigational Site 10309
Bellevue, Ohio, United States, 44811
Teva Investigational Site 10317
Columbus, Ohio, United States, 43221
Teva Investigational Site 10325
Dayton, Ohio, United States, 45417
United States, Pennsylvania
Teva Investigational Site 10340
Hershey, Pennsylvania, United States, 17033-0850
Teva Investigational Site 10331
Philadelphia, Pennsylvania, United States, 19104
United States, Tennessee
Teva Investigational Site 10313
Cordova, Tennessee, United States, 38018
Teva Investigational Site 10324
Franklin, Tennessee, United States, 37064
Teva Investigational Site 10318
Nashville, Tennessee, United States, 37205
United States, Utah
Teva Investigational Site 10319
Salt Lake City, Utah, United States, 84103
United States, Virginia
Teva Investigational Site 10330
Newport News, Virginia, United States, 23601
Teva Investigational Site 10311
Roanoke, Virginia, United States, 24018
United States, Washington
Teva Investigational Site 10335
Seattle, Washington, United States, 98122
Austria
Teva Investigational Site 33013
Innsbruck, Austria, A-6020
Teva Investigational Site 33014
Linz, Austria, 4020
Teva Investigational Site 33016
Wien, Austria, 1010
Teva Investigational Site 33015
Wien, Austria, 1090
Belarus
Teva Investigational Site 68010
Gomel, Belarus, 246029
Teva Investigational Site 68013
Grodno, Belarus, 230027
Teva Investigational Site 68012
Minsk, Belarus, 220026
Teva Investigational Site 68009
Minsk, Belarus, 220114
Teva Investigational Site 68008
Minsk, Belarus, 220116
Teva Investigational Site 68011
Vitebsk, Belarus, 210023
Belgium
Teva Investigational Site 37023
Charleroi, Belgium, 6000
Teva Investigational Site 37024
Sijsele, Belgium, 8340
Bosnia and Herzegovina
Teva Investigational Site 69008
Mostar, Bosnia and Herzegovina, 88000
Teva Investigational Site 69006
Sarajevo, Bosnia and Herzegovina, 71000
Teva Investigational Site 69009
Tuzla, Bosnia and Herzegovina, 75000
Bulgaria
Teva Investigational Site 59039
Pleven, Bulgaria, 5800
Teva Investigational Site 59040
Pleven, Bulgaria, 5800
Teva Investigational Site 59060
Pleven, Bulgaria, 5800
Teva Investigational Site 59062
Plovdiv, Bulgaria, 4002
Teva Investigational Site 59061
Ruse, Bulgaria, 7003
Teva Investigational Site 59055
Shumen, Bulgaria, 9700
Teva Investigational Site 59048
Sofia, Bulgaria, 1113
Teva Investigational Site 59052
Sofia, Bulgaria, 1113
Teva Investigational Site 59057
Sofia, Bulgaria, 1113
Teva Investigational Site 59050
Sofia, Bulgaria, 1142
Teva Investigational Site 59044
Sofia, Bulgaria, 1309
Teva Investigational Site 59063
Sofia, Bulgaria, 1407
Teva Investigational Site 59038
Sofia, Bulgaria, 1431
Teva Investigational Site 59043
Sofia, Bulgaria, 1431
Teva Investigational Site 59058
Sofia, Bulgaria, 1431
Teva Investigational Site 59041
Sofia, Bulgaria, 1527
Teva Investigational Site 59042
Sofia, Bulgaria, 1606
Teva Investigational Site 59054
Sofia, Bulgaria, 1606
Teva Investigational Site 59059
Sofia, Bulgaria, 1606
Teva Investigational Site 59045
Sofia, Bulgaria, 1750
Teva Investigational Site 59049
Stara Zagora, Bulgaria, 6003
Teva Investigational Site 59046
Varna, Bulgaria, 9010
Teva Investigational Site 59051
Veliko Tarnovo, Bulgaria, 5000
Teva Investigational Site 59053
Veliko Tarnovo, Bulgaria, 5100
Canada, Alberta
Teva Investigational Site 11013
Edmonton, Alberta, Canada, T6G 1Z1
Canada, British Columbia
Teva Investigational Site 11014
Burnaby, British Columbia, Canada, V5G 2X6
Canada
Teva Investigational Site 11015
Ottawa, Canada, K1H 8L6
Teva Investigational Site 11016
Saskatoon, Canada, S7K 0M7
Croatia
Teva Investigational Site 60010
Osijek, Croatia, 31 000
Teva Investigational Site 60011
Varazdin, Croatia, 42000
Teva Investigational Site 60009
Zagreb, Croatia, 10000
Czechia
Teva Investigational Site 54042
Brno, Czechia, 602 00
Teva Investigational Site 54043
Havirov, Czechia, 736 01
Teva Investigational Site 54047
Hradec Kralove 3, Czechia, 50003
Teva Investigational Site 54046
Jihlava, Czechia, 58633
Teva Investigational Site 54044
Olomouc, Czechia, 779 00
Teva Investigational Site 54045
Ostrava, Czechia, 702 00
Teva Investigational Site 54049
Praha 10, Czechia, 100 31
Teva Investigational Site 54041
Praha, Czechia, 104 00
Teva Investigational Site 54048
Teplice, Czechia, 415 29
Estonia
Teva Investigational Site 55005
Parnu, Estonia, 80010
Teva Investigational Site 55008
Tallinn, Estonia, EE-10138
Teva Investigational Site 55006
Tallinn, Estonia, EE-10617
Teva Investigational Site 55007
Tartu, Estonia, EE-51014
France
Teva Investigational Site 35075
Clermont-Ferrand Cedex 1, France, 63003
Teva Investigational Site 35077
Dijon, France
Teva Investigational Site 35073
Lille, France, 59000
Teva Investigational Site 35076
Lyon cedex 04, France, 69317
Teva Investigational Site 35079
Nimes, France, 30029
Georgia
Teva Investigational Site 81018
Tbilisi, Georgia, 0112
Teva Investigational Site 81014
Tbilisi, Georgia, 0141
Teva Investigational Site 81015
Tbilisi, Georgia, 0179
Teva Investigational Site 81019
Tbilisi, Georgia, 0179
Teva Investigational Site 81017
Tbilisi, Georgia, 0186
Teva Investigational Site 81016
Tbilisi, Georgia, 0194
Germany
Teva Investigational Site 32199
Bad Mergentheim, Germany, 97980
Teva Investigational Site 32195
Berg, Germany, 82335
Teva Investigational Site 32200
Berlin, Germany, 10117
Teva Investigational Site 32186
Berlin, Germany, 10437
Teva Investigational Site 32176
Berlin, Germany, 10625
Teva Investigational Site 32174
Berlin, Germany, 10713
Teva Investigational Site 32198
Berlin, Germany, 12163
Teva Investigational Site 32177
Bochum, Germany, 44791
Teva Investigational Site 32193
Dresden, Germany, 01307
Teva Investigational Site 32184
Erbach, Germany, 64711
Teva Investigational Site 32189
Erfurt, Germany, 99089
Teva Investigational Site 32203
Giessen, Germany, 35385
Teva Investigational Site 32202
Goettigen, Germany, 37075
Teva Investigational Site 32196
Halle (Saale), Germany, 06120
Teva Investigational Site 32181
Hamburg, Germany, 20246
Teva Investigational Site 32179
Hamburg, Germany, 22083
Teva Investigational Site 32182
Hannover, Germany, 30171
Teva Investigational Site 32175
Ibbenburen, Germany, 49477
Teva Investigational Site 32201
Jena, Germany, 07743
Teva Investigational Site 32183
Koln, Germany, 50935
Teva Investigational Site 32190
Leipzig, Germany, 4103
Teva Investigational Site 32185
Magdeburg, Germany, 39120
Teva Investigational Site 32191
Rostock, Germany, 18147
Teva Investigational Site 32194
Teupitz, Germany, 15755
Teva Investigational Site 32173
Ulm, Germany, 89081
Teva Investigational Site 32197
Wermsdorf, Germany, 04773
Teva Investigational Site 32188
Westerstede, Germany, 26655
Greece
Teva Investigational Site 63027
Athens, Greece, 115 28
Teva Investigational Site 63024
Athens, Greece, 11525
Teva Investigational Site 63029
Chaidari, Greece, 12462
Teva Investigational Site 63026
Heraklion, Greece, 71110
Teva Investigational Site 63030
Larisa, Greece, 41110
Teva Investigational Site 63025
Thessaloniki, Greece, 54636
Teva Investigational Site 63028
Thessaloniki, Greece, 57010
Hungary
Teva Investigational Site 51046
Budapest, Hungary, 1134
Teva Investigational Site 51043
Debrecen, Hungary, 4043
Teva Investigational Site 51045
Eger, Hungary, H-3300
Teva Investigational Site 51044
Kaposvar, Hungary, H-7400
Israel
Teva Investigational Site 80023
Haifa, Israel, 31096
Teva Investigational Site 80024
Haifa, Israel, 31096
Teva Investigational Site 80020
Ramat Gan, Israel, 5262160
Teva Investigational Site 80021
Tel Aviv, Israel, 64239
Italy
Teva Investigational Site 30037
Bologna, Italy, 40139
Teva Investigational Site 30031
Castelfiorentino, Italy, 50051
Teva Investigational Site 30030
Cefalu, Italy, 90015
Teva Investigational Site 30032
Chieti, Italy, 66100
Teva Investigational Site 30024
Firenze, Italy, 50139
Teva Investigational Site 30029
Gallarate, Italy, 21013
Teva Investigational Site 30023
Milano, Italy, 20132
Teva Investigational Site 30039
Milano, Italy, 20133
Teva Investigational Site 30034
Napoli, Italy, 80131
Teva Investigational Site 30027
Palermo, Italy, 90146
Teva Investigational Site 30028
Rome, Italy, 00149
Teva Investigational Site 30025
Rome, Italy, 00163
Teva Investigational Site 30026
Rome, Italy, 00168
Teva Investigational Site 30035
Rome, Italy, 00178
Teva Investigational Site 30040
Verona, Italy, 37134
Korea, Republic of
Teva Investigational Site 87001
Goyang-si, Korea, Republic of, 410-769
Teva Investigational Site 87003
Seoul, Korea, Republic of, 03080
Teva Investigational Site 87002
Seoul, Korea, Republic of, 138-736
Latvia
Teva Investigational Site 56006
Riga, Latvia, 1038
Teva Investigational Site 56005
Riga, Latvia, LV-1005
Macedonia, The Former Yugoslav Republic of
Teva Investigational Site 65010
Skopje, Macedonia, The Former Yugoslav Republic of, 1000
Teva Investigational Site 65011
Skopje, Macedonia, The Former Yugoslav Republic of, 1000
Teva Investigational Site 65012
Skopje, Macedonia, The Former Yugoslav Republic of, 1000
Moldova, Republic of
Teva Investigational Site 70006
Chisinau, Moldova, Republic of, 2001
Teva Investigational Site 70005
Chisinau, Moldova, Republic of, 2024
Teva Investigational Site 70008
Chisinau, Moldova, Republic of, 2028
Montenegro
Teva Investigational Site 66002
Podgorica, Montenegro, 20000
Poland
Teva Investigational Site 53066
Bialystok, Poland, 15-276
Teva Investigational Site 53071
Bialystok, Poland, 15-402
Teva Investigational Site 53085
Bydgoszcz, Poland, 85-654
Teva Investigational Site 53084
Czestochowa, Poland, 42-280
Teva Investigational Site 53069
Gdansk, Poland, 80-299
Teva Investigational Site 53083
Gdansk, Poland, 80-546
Teva Investigational Site 53067
Gdansk, Poland, 80-803
Teva Investigational Site 53078
Grodzisk Mazowiecki, Poland, 05-825
Teva Investigational Site 53080
Katowice, Poland, 40-555
Teva Investigational Site 53081
Katowice, Poland, 40-650
Teva Investigational Site 53073
Katowice, Poland, 40-684
Teva Investigational Site 53070
Katowice, Poland, 40-749
Teva Investigational Site 53074
Katowice, Poland, 40-752
Teva Investigational Site 53064
Konskie, Poland, 26-200
Teva Investigational Site 53065
Konstancin-Jeziorna, Poland, 05-510
Teva Investigational Site 53072
Koscierzyna, Poland, 83-400
Teva Investigational Site 53063
Lodz, Poland, 90-324
Teva Investigational Site 53079
Olsztyn, Poland, 10-560
Teva Investigational Site 53068
Plewiska, Poland, 62-064
Teva Investigational Site 53076
Szczecin, Poland, 70-111
Romania
Teva Investigational Site 52045
Balotesti, Romania, 77015
Teva Investigational Site 52041
Bucharest, Romania, 012071
Teva Investigational Site 52050
Bucuresti, Romania, 020125
Teva Investigational Site 52037
Bucuresti, Romania, 022328
Teva Investigational Site 52034
Bucuresti, Romania, 050098
Teva Investigational Site 52040
Cluj-Napoca, Romania, 400006
Teva Investigational Site 52036
Cluj-Napoca, Romania, 400437
Teva Investigational Site 52038
Constanta, Romania, 900123
Teva Investigational Site 52044
Constanta, Romania, 900591
Teva Investigational Site 52048
Craiova, Romania, 200473
Teva Investigational Site 52049
Hunedoara, Romania, 331057
Teva Investigational Site 52042
Iasi, Romania, 700661
Teva Investigational Site 52039
Oradea, Romania, 410108
Teva Investigational Site 52047
Piatra-Neamt, Romania, 610136
Teva Investigational Site 52046
Sibiu, Romania, 550245
Teva Investigational Site 52035
Targu Mures, Romania
Teva Investigational Site 52043
Timisoara, Romania, 100182
Russian Federation
Teva Investigational Site 50130
Barnaul, Russian Federation, 656024
Teva Investigational Site 50129
Chelyabinsk, Russian Federation, 454021
Teva Investigational Site 50208
Kazan, Russian Federation, 420021
Teva Investigational Site 50148
Kemerovo, Russian Federation, 650061
Teva Investigational Site 50144
Krasnodar, Russian Federation, 350012
Teva Investigational Site 50147
Moscow, Russian Federation, 119021
Teva Investigational Site 50124
Moscow, Russian Federation, 127015
Teva Investigational Site 50133
Moscow, Russian Federation, 129110
Teva Investigational Site 50146
Moscow, Russian Federation, 129128
Teva Investigational Site 50141
Nizhny Novgorod, Russian Federation, 603076
Teva Investigational Site 50128
Nizhny Novgorod, Russian Federation, 603155
Teva Investigational Site 50131
Nizhny Novgorod, Russian Federation, 603155
Teva Investigational Site 50127
Perm, Russian Federation, 614990
Teva Investigational Site 50143
Rostov-on-Don, Russian Federation, 344015
Teva Investigational Site 50149
Rostov-on-Don, Russian Federation, 344022
Teva Investigational Site 50126
Saint Petersburg, Russian Federation, 191186
Teva Investigational Site 50140
Saint Petersburg, Russian Federation, 197022
Teva Investigational Site 50138
Samara, Russian Federation, 443095
Teva Investigational Site 50135
Saratov, Russian Federation, 410054
Teva Investigational Site 50136
Smolensk, Russian Federation, 214018
Teva Investigational Site 50137
St. Petersburg, Russian Federation, 194354
Teva Investigational Site 50125
Tomsk, Russian Federation, 634050
Teva Investigational Site 50139
Tyumen, Russian Federation, 625000
Teva Investigational Site 50134
Ufa, Russian Federation, 450007
Teva Investigational Site 50132
Volgograd, Russian Federation, 400138
Teva Investigational Site 50142
Yaroslavl, Russian Federation, 150030
Serbia
Teva Investigational Site 61025
Belgrade, Serbia, 11000
Teva Investigational Site 61027
Belgrade, Serbia, 11000
Teva Investigational Site 61024
Belgrade, Serbia, 11080
Teva Investigational Site 61018
Cacak, Serbia, 32000
Teva Investigational Site 61015
Kragujevac, Serbia, 34000
Teva Investigational Site 61014
Nis, Serbia, 18000
Teva Investigational Site 61019
Sombor, Serbia, 25000
Teva Investigational Site 61016
Subotica, Serbia, 24000
Teva Investigational Site 61017
Uzice, Serbia, 31000
Teva Investigational Site 61022
Valjevo, Serbia, 14000
Teva Investigational Site 61026
Vrbas, Serbia, 21460
Teva Investigational Site 61021
Zrenjanin, Serbia, 23000
Slovakia
Teva Investigational Site 62012
Hlohovec, Slovakia, 92001
Teva Investigational Site 62013
Trnava, Slovakia, 917 75
Spain
Teva Investigational Site 31035
Barcelona, Spain, 08025
Teva Investigational Site 31030
Barcelona, Spain, 08035
Teva Investigational Site 31031
Getafe, Spain, 28905
Teva Investigational Site 31036
L'Hospitalet de Llobregat, Spain, 08907
Teva Investigational Site 31032
Madrid, Spain, 28040
Teva Investigational Site 31034
Madrid, Spain, 28046
Teva Investigational Site 31033
Navarro, Spain, 31008
Teva Investigational Site 31039
Oviedo, Spain, 33011
Teva Investigational Site 31037
Salt, Spain, 17190
Ukraine
Teva Investigational Site 58087
Chernihiv, Ukraine, 14001
Teva Investigational Site 58083
Chernivtsi, Ukraine, 58018
Teva Investigational Site 58077
Dnipropetrovsk, Ukraine, 49044
Teva Investigational Site 58088
Ivano-Frankivsk, Ukraine, 76008
Teva Investigational Site 58076
Ivano-Frankivsk, Ukraine
Teva Investigational Site 58116
Kharkiv, Ukraine, 61068
Teva Investigational Site 58084
Kharkiv, Ukraine, 61103
Teva Investigational Site 58089
Kiev, Ukraine, 04112
Teva Investigational Site 58073
Kyiv, Ukraine, 01601
Teva Investigational Site 58078
Kyiv, Ukraine, 03110
Teva Investigational Site 58081
Kyiv, Ukraine, 03115
Teva Investigational Site 58115
Lviv, Ukraine, 79013
Teva Investigational Site 58086
Lviv, Ukraine, 79059
Teva Investigational Site 58074
Odesa, Ukraine, 65025
Teva Investigational Site 58085
Odessa, Ukraine, 65014
Teva Investigational Site 58082
Poltava, Ukraine, 36024
Teva Investigational Site 58080
Simferopol, Ukraine, 95000
Teva Investigational Site 58072
Vinnytsya, Ukraine, 21005
Teva Investigational Site 58079
Zaporizhzhya, Ukraine, 69035
Teva Investigational Site 58075
Zaporizhzhya, Ukraine, 69600
United Kingdom
Teva Investigational Site 34015
Glasgow, United Kingdom, G51 4TF
Teva Investigational Site 34011
Liverpool, United Kingdom, B0T 1K0
Teva Investigational Site 34010
Liverpool, United Kingdom, L9 7LJ
Teva Investigational Site 34019
London, United Kingdom, E1 1BB
Teva Investigational Site 34016
Salford, United Kingdom, M6 8HD
Teva Investigational Site 34017
Sheffield, United Kingdom, S10 2JF
Teva Investigational Site 34013
Stoke-on-Trent, United Kingdom, ST4 6QG
Sponsors and Collaborators
Teva Branded Pharmaceutical Products, R&D Inc.
Investigators
Layout table for investigator information
Study Director: Teva Medical Expert, MD Teva Pharmaceuticals USA

Layout table for additonal information
Responsible Party: Teva Branded Pharmaceutical Products, R&D Inc.
ClinicalTrials.gov Identifier: NCT01707992     History of Changes
Other Study ID Numbers: LAQ-MS-305
2012-003647-30 ( EudraCT Number )
First Posted: October 16, 2012    Key Record Dates
Results First Posted: March 13, 2019
Last Update Posted: March 13, 2019
Last Verified: February 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases